Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELUNE: Secukinumab 300 mg vs placebo in active lupus nephritis
jRCT2080225121Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) and systemic lupus erythematosus (SLE) comparing Secukinumab 300 mg + standard-of-care with Placebo + standard-of-care (2 arms). Started Mar 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080225121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225121.